Ho-Chou Tu

机构：Alnylam Pharmaceuticals (United States) · ORCID：0009-0006-8904-8239

发表论文 44 篇 · 总被引 2765 次 · h-index 14

代表论文

• Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation (2021 · Nature Metabolism · 被引 102)
• Rare coding variants in DNA damage repair genes associated with timing of natural menopause (2021 · Human Genetics and Genomics Advances · 被引 51)
• Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD (2023 · Metabolism · 被引 30)
• Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR (2024 · Hypertension · 被引 21)
• Targeting Angiotensinogen With N -Acetylgalactosamine–Conjugated Small Interfering RNA to Reduce Blood Pressure (2023 · Arteriosclerosis Thrombosis and Vascular Biology · 被引 20)
• AAV-mediated hepatic expression of SLC30A10 and the Thr95Ile variant attenuates manganese excess and other phenotypes in Slc30a10-deficient mice (2024 · Journal of Biological Chemistry · 被引 9)